Advertisement

Breast Cancer Research and Treatment

, Volume 16, Issue 1, pp 23–28 | Cite as

Mammary serum antigen (MSA) in advanced breast cancer

  • Y. C. Smart
  • J. F. Stewart
  • L. D. Bartlett
  • J. H. Brien
  • J. F. Forbes
  • R. C. Burton
Report

Summary

An Enzyme Linked Immunosorbent Assay (ELISA) based on a monoclonal antibody, 3E1.2, was used to measure circulating Mammary Serum Antigen (MSA) in a study of 123 advanced breast cancer patients. Fifty two patients were monitored serially to investigate whether measurements of circulating MSA levels were of value in the management of advanced breast cancer patients on palliative therapy. Analysis of variance showed that circulating MSA levels at first presentation correlated with disease status both at initial presentation (p = 0.01) and also 4 months later (p = 0.003). At first presentation, the circulating MSA level also significantly correlated with the number of metastatic sites (p = 0.04), but this did not hold at 4 months. The circulating MSA levels did not at any time correlate with the type of treatment given nor age of the patient. We conclude that MSA might ultimately be useful in the management of advanced breast cancer patients as a prognostic marker for the course of the disease and for monitoring patient response to palliative hormonal therapy and chemotherapy.

Key words

advanced breast cancer clinical status mammary serum antigen (MSA) monoclonal antibody palliative therapy serum markers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stacker S, Lowe MG, McKatee K, Thompson CH, Lichtenstein M, Leyden M, Salehi N, Andrews J, McKenzie IFC: Detection of breast cancer using monoclonal antibody 3E1.2. In: Ceriani RL (ed) Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Martinus Nijhoff Publishers, Boston, 1985, pp 233–247Google Scholar
  2. 2.
    Stacker SA, Thompson C, Riglar C, McKenzie IFC: A new breast carcinoma antigen defined by a monoclonal antibody. J Natl Cancer Inst 75: 801–811, 1985PubMedGoogle Scholar
  3. 3.
    Tjandra JJ, Russell IS, Collins JP, Stacker SA, McKenzie IFC: Application of Mammary Serum Antigen in the management of breast cancer — A preliminary report. Br J Surg 75: 811–817, 1988PubMedGoogle Scholar
  4. 4.
    Stacker SA, Sacks NPM, Golder J, Tjandra JJ, Thompson CH, Smithyman A, McKenzie IFC: Evaluation of MSA as a serum marker in breast cancer: A comparison with CEA. Br J Cancer 57: 298–303, 1988PubMedGoogle Scholar
  5. 5.
    Sacks NPM, Stacker SA, Thompson CH, Collins JP, Russell IS, Sullivan JA, McKenzie IFC: Comparison of Mammary Serum Antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer. Br J Cancer 56: 820–824, 1987PubMedGoogle Scholar
  6. 6.
    Smart YC, Rogers KM, Brien JH, Stewart JF, Burton RC: Factors affecting MSA levels in normal women and women with breast cancer. Aust N Z J Surg 59: 805–809, 1989PubMedGoogle Scholar
  7. 7.
    Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298, 1977PubMedGoogle Scholar
  8. 8.
    Stacker S, Sacks N, Thompson C, Smart C, Burton R, Golder J, Xing P-X, McKenzie IFC: A serum test for the diagnosis and monitoring the progress of breast cancer. In: Ceriani RL (ed) Immunological Approaches to the Diagnosis and Therapy of Breast Cancer. Plenum, New York, 1987, pp 217–227Google Scholar
  9. 9.
    Zar JH: Biostatistical Analysis. Prentice-Hall, N.J., 1974Google Scholar
  10. 10.
    McGuire WL, Dickson RB, Osborne CK, Salomon D: The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat 12: 205–211, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Y. C. Smart
    • 1
  • J. F. Stewart
    • 2
  • L. D. Bartlett
    • 3
  • J. H. Brien
    • 1
  • J. F. Forbes
    • 2
  • R. C. Burton
    • 1
  1. 1.Discipline of Surgical Science, Faculty of MedicineUniversity of NewcastleNewcastleAustralia
  2. 2.Oncology Unit, Newcastle Mater Misericordiae HospitalNewcastleAustralia
  3. 3.Auspharm Institute for Mucosal Immunology, Technology CenterNewcastleAustralia

Personalised recommendations